Calamos Wealth Management LLC Has $1.65 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Calamos Wealth Management LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 24.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 65,121 shares of the biopharmaceutical company's stock after buying an additional 12,647 shares during the quarter. Calamos Wealth Management LLC's holdings in Pfizer were worth $1,650,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Bessemer Group Inc. raised its holdings in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in shares of Pfizer in the first quarter valued at about $8,283,000. Alta Advisers Ltd raised its holdings in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after buying an additional 13,100 shares during the last quarter. WCM Investment Management LLC raised its holdings in shares of Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after buying an additional 10,051 shares during the last quarter. Finally, Sage Mountain Advisors LLC raised its holdings in shares of Pfizer by 7.3% in the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after buying an additional 1,404 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.5%

Shares of Pfizer stock traded up $0.13 during trading on Friday, hitting $25.45. 27,104,580 shares of the company were exchanged, compared to its average volume of 41,625,077. The firm has a market capitalization of $144.66 billion, a P/E ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm's fifty day moving average price is $23.67 and its 200 day moving average price is $24.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

A number of research analysts recently issued reports on PFE shares. The Goldman Sachs Group lifted their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America boosted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research boosted their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Finally, BMO Capital Markets dropped their price objective on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.